Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.39 |
| ▸ | HTR3A | P46098 | 3/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653612 | 0.78 | CHRNA7 (0.52) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5651260 | 0.75 | DGAT1 (0.48) | DGAT1KCNH2 | |
| SCHEMBL5648361 | 0.73 | FLT3 (0.43) | DGAT1SOAT1KCNH2 | |
| SCHEMBL5653613 | 0.71 | CHRNA7 (0.52) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL5997360 | 0.68 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL1964278 | 0.68 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL1966249 | 0.68 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL13849257 | 0.68 | CHEK1 (0.46) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL2228213 | 0.67 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BALOX15 | |
| SCHEMBL2228216 | 0.67 | CHRNA7 (0.71) | CHRNA7HTR3AHTR3EHTR3BALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | DGAT1 2386/4885CHRNA7 3434/4885HTR3A 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.